Evidence map›Paper›PMID 34924015›Full record

ReviewDiabetology & metabolic syndrome2021

A review of reusable insulin pens and features of TouStar-a new reusable pen with a dedicated cartridge.

Robert Veasey, Carolin A Ruf, Dmitri Bogatirsky, Jukka Westerbacka, Arnd Friedrichs, Mona Abdel-Tawab, Steffen Adler, Senthilnathan Mohanasundaram

Open access · goldAbstract readReview
In one paragraph

Review in Diabetology & metabolic syndrome, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 22 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Robert VeaseyDCA Design International Ltd., Warwick, UK.
Carolin A RufSanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
Dmitri BogatirskySanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
Jukka WesterbackaSanofi, Paris, France.
Arnd FriedrichsDr. Arnd Friedrichs Unternehmensberatung, Görlitz, Germany.
Mona Abdel-TawabZentrallaboratorium Deutscher Apotheker, Eschborn, Germany.
Steffen AdlerDr. Arnd Friedrichs Unternehmensberatung, Görlitz, Germany.
Senthilnathan MohanasundaramSanofi, Mumbai, India. senthilnathan.mohanasundaram@sanofi.com.
Sanofi (Germany) · DEDCA (United Kingdom) · GBSanofi (France) · FRSanofi (India) · INZentrallaboratorium Deutscher Apotheker · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the introduction of the first reusable insulin pen, the advancement in the design of these pens is still ongoing to develop a safe, more efficacious, less painful, and easy to use insulin pen device. MAIN BODY: Possible errors in insulin delivery can occur at any stage of insulin delivery such as during the prescription stage, dispensing stage, or at administration stage. Mismatch of the insulin pen and cartridge is not uncommon and is a potential risk for individuals with diabetes due to serious consequences associated with incorrect insulin usage. The similarities in insulin cartridges of different manufacturers with regard to color and product names could lead to mix-up of insulin pens and cartridges. These unmet needs have led to the ongoing search for developing insulin pens that can address these errors and provide more efficacious and safer choices for patients with diabetes.

conclusionThis review provides an overview of currently available reusable pens in the market and highlights the features of TouStar

Indexed as

CartridgeDiabetes mellitusGlargine 300 U/mLInsulin pen

Identifiers

PMID34924015
PMCPMC8684684
OpenAlexW4200001668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.